GlassScriptPhysician profile
Anuranjan Bist
NPI 1346349990
$1,223.37
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $374 · 2021: $62.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $197.23 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $159.51 | 2019-2020 | |
| Shire North American Group INC | $155.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.77 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.35 | 2020-2021 | |
| Allergan, INC. | $79.05 | 2019-2020 | |
| Lundbeck LLC | $76.16 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $72.48 | 2019 | |
| Neos Therapeutics, LP | $61.15 | 2019-2020 | |
| Brainsway USA INC | $53.03 | 2019 | |
| Eisai INC. | $49.95 | 2020 | |
| Avanir Pharmaceuticals, INC. | $48.11 | 2020 | |
| Neurocrine Biosciences, INC. | $29.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $21.80 | 2020 | |
| Sunovion Pharmaceuticals INC. | $17.77 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $14.02 | 2019 | |
| Adlon Therapeutics L.P. | $11.56 | 2020 | |
| Ironshore Pharmaceuticals INC. | $11.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuranjan Bist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.